ZURICH, Oct 28 (Reuters) – Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Claire Fu, Eduardo Baptista and Laurie Chen SINGAPORE/BEIJING, Oct 28 (Reuters) - China's proposed…
By Claire Fu, Eduardo Baptista and Laurie Chen SINGAPORE/BEIJING, Oct 28 (Reuters) - China's proposed…
Oct 28 (Reuters) - Cementos Molins SA: * 9-MONTH NET PROFIT €172 MILLION * SEES…
VIDEO SHOWS: HIGHLIGHTS FOR NEW YORK KNICKS BEATING DETROIT PISTONS 111-97 COMPLETE SHOTLIST TO FOLLOW…
SOUTH KOREA MEDIA AND COMMUNICATION COMMISSION FINES GOOGLE 42.9 BLN WON, APPLE 20.8 BLN WON…
By Rachel More BERLIN, Oct 28 (Reuters) - From a single-model company rising from the…